Innovative cancer therapy

Enlarge

Eisbach Bio GmbH, founded in year 2019 as a spin-off from the Biomedical Center (BMC) of LMU Munich, has established itself as a leading company in the field of precision oncology. The company has now received the prestigious Texas Therapeutics Company Award from the Cancer Prevention and Research Institute of Texas (CPRIT). The grant will support the clinical development of EIS-12656, targeting challenging cancers with homologous recombination deficiencies (HRD).

The next milestone for Eisbach Bio is to conduct Phase I/II clinical trials at the renowned MD Anderson Cancer Center at the University of Texas, advancing hope for patients with limited treatment options.

For more information, visit the Eisbach Bio website.